• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

食管癌的多模态治疗时代的外科治疗。

Surgical treatment of esophageal cancer in the era of multimodality management.

机构信息

Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Moscow Clinical Scientific Center, Moscow, Russia.

出版信息

Ann N Y Acad Sci. 2018 Dec;1434(1):192-209. doi: 10.1111/nyas.13677. Epub 2018 May 15.

DOI:10.1111/nyas.13677
PMID:29761863
Abstract

Over the last decades, the treatment of resectable esophageal cancer has evolved into a multidisciplinary process in which all players are essential for treatment to be successful. Medical oncologists and radiation oncologists have been increasingly involved since the implementation of neoadjuvant therapy, which has been shown to improve survival. Although esophagectomy is still considered the cornerstone of curative treatment for locally advanced esophageal cancer, it remains associated with considerable postoperative morbidity, despite promising results of minimally invasive techniques. In this light, both physical status and response to neoadjuvant therapy may be important factors for selecting patients who will benefit from surgery. Furthermore, it is important to optimize the entire perioperative trajectory: from the initial outpatient clinic visit to postoperative discharge. Enhanced recovery after surgery is increasingly recognized for esophagectomy and emphasizes perioperative aspects, such as nutrition, physiotherapy, and pain management. To date, several facets of esophageal cancer treatment remain topics of debate, such as the preferred neoadjuvant treatment, anastomotic technique, extent of lymphadenectomy, organization of postoperative care, and the role of surgery beyond locally advanced disease. Here, we describe the current and future perspectives in the surgical treatment of patients with esophageal cancer in the context of the available literature.

摘要

在过去的几十年中,可切除食管癌的治疗已经发展成为一个多学科的过程,所有参与者对于治疗的成功都是至关重要的。自从新辅助治疗实施以来,医学肿瘤学家和放射肿瘤学家的参与度越来越高,因为新辅助治疗已经被证明可以提高生存率。尽管食管切除术仍然被认为是局部晚期食管癌的根治性治疗的基石,但即使微创手术的结果令人鼓舞,它仍然与相当大的术后发病率相关。有鉴于此,身体状况和对新辅助治疗的反应可能是选择将从手术中获益的患者的重要因素。此外,优化整个围手术期的轨迹也很重要:从最初的门诊就诊到术后出院。术后恢复加速计划在食管切除术中的应用越来越受到重视,强调了围手术期的方面,如营养、物理治疗和疼痛管理。迄今为止,食管癌治疗的几个方面仍然是争议的话题,例如首选的新辅助治疗、吻合技术、淋巴结清扫范围、术后护理的组织以及手术在局部晚期疾病之外的作用。在这里,我们根据现有文献描述了在食管癌患者的外科治疗方面的当前和未来的观点。

相似文献

1
Surgical treatment of esophageal cancer in the era of multimodality management.食管癌的多模态治疗时代的外科治疗。
Ann N Y Acad Sci. 2018 Dec;1434(1):192-209. doi: 10.1111/nyas.13677. Epub 2018 May 15.
2
Optimal surgical approach for esophageal cancer in the era of minimally invasive esophagectomy and neoadjuvant therapy.微创食管切除术和新辅助治疗时代食管癌的最佳手术方法
Dis Esophagus. 2016 Oct;29(7):773-779. doi: 10.1111/dote.12407. Epub 2015 Sep 18.
3
Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.晚期食管癌的新辅助治疗:对手术管理的影响
Gen Thorac Cardiovasc Surg. 2016 Jul;64(7):386-94. doi: 10.1007/s11748-016-0655-y. Epub 2016 May 10.
4
Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.淋巴结清扫范围对新辅助化疗后经胸段食管癌切除术患者生存率的影响
Ann Surg. 2017 Apr;265(4):750-756. doi: 10.1097/SLA.0000000000001737.
5
The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.无论新辅助放化疗或淋巴结清扫范围如何,转移性淋巴结数量以及转移淋巴结与检查淋巴结的比例都是食管癌独立的预后因素。
Ann Surg. 2008 Feb;247(2):365-71. doi: 10.1097/SLA.0b013e31815aaadf.
6
Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.新辅助治疗后开放与微创Ivor Lewis食管癌切除术的疗效
Ann Thorac Surg. 2016 Mar;101(3):1097-103. doi: 10.1016/j.athoracsur.2015.09.062. Epub 2015 Dec 1.
7
Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.新辅助放化疗后行食管切除术治疗初治可切除的伴有多发淋巴结转移的食管鳞状细胞癌。
Dis Esophagus. 2005;18(6):388-97. doi: 10.1111/j.1442-2050.2005.00521.x.
8
Nutritional optimization during neoadjuvant therapy prior to surgical resection of esophageal cancer-a narrative review.食管癌手术切除术前新辅助治疗期间的营养优化——一篇叙述性综述
Dis Esophagus. 2018 Jan 1;31(1):1-11. doi: 10.1093/dote/dox110.
9
Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.食管癌根治术联合日本式扩大三野淋巴结清扫术后新辅助放化疗的疗效与安全性
Anticancer Res. 2017 Oct;37(10):5837-5843. doi: 10.21873/anticanres.12027.
10
Transhiatal Esophagectomy for Esophageal Cancer.经胸食管切除术治疗食管癌。
J Laparoendosc Adv Surg Tech A. 2016 Oct;26(10):752-756. doi: 10.1089/lap.2016.29009.jpn. Epub 2016 Aug 22.

引用本文的文献

1
Qige San regulates paclitaxel resistance in esophageal cancer by targeting ferroptosis.芪葛散通过靶向铁死亡调节食管癌对紫杉醇的耐药性。
World J Gastrointest Oncol. 2025 Aug 15;17(8):106783. doi: 10.4251/wjgo.v17.i8.106783.
2
The Effect of Minimal-Dose S-Ketamine Administration Post-Surgery on Opioids Consumption and Functional Rehabilitation Exercises in Patients Undergoing Minimally Invasive Radical Resection of Esophageal Cancer.小剂量S-氯胺酮术后给药对微创食管癌根治术患者阿片类药物消耗及功能康复锻炼的影响
Ther Clin Risk Manag. 2025 Jul 5;21:1033-1044. doi: 10.2147/TCRM.S527262. eCollection 2025.
3
Comprehensive risk score of the E-PASS scoring system serves a prognostic indicator for patients after neoadjuvant therapy and curative esophageal cancer surgery: a multicenter retrospective study.
E-PASS评分系统的综合风险评分可作为新辅助治疗后及食管癌根治性手术后患者的预后指标:一项多中心回顾性研究
Front Oncol. 2025 Jun 6;15:1617683. doi: 10.3389/fonc.2025.1617683. eCollection 2025.
4
Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) vs. Conventional Minimally Invasive Esophagectomy (MIE) for Esophageal Cancer: A Nationwide Inpatient Sample Analysis from 2017 to 2020.机器人辅助微创食管切除术(RAMIE)与传统微创食管切除术(MIE)治疗食管癌的比较:2017年至2020年全国住院患者样本分析
Ann Thorac Cardiovasc Surg. 2025;31(1). doi: 10.5761/atcs.oa.25-00017.
5
PSPH promotes the proliferation and metastasis of esophageal squamous cell carcinoma through MAPK signaling pathways.磷酸丝氨酸磷酸酶通过丝裂原活化蛋白激酶信号通路促进食管鳞状细胞癌的增殖和转移。
Am J Cancer Res. 2025 Apr 25;15(4):1919-1931. doi: 10.62347/OGMW9514. eCollection 2025.
6
Artificial intelligence for intraoperative video analysis in robotic-assisted esophagectomy.用于机器人辅助食管切除术术中视频分析的人工智能
Surg Endosc. 2025 May;39(5):2774-2783. doi: 10.1007/s00464-025-11685-6. Epub 2025 Mar 31.
7
AGTR1 potentiates the chemotherapeutic efficacy of cisplatin in esophageal carcinoma through elevation of intracellular Ca and induction of apoptosis.血管紧张素Ⅱ1型受体(AGTR1)通过升高细胞内钙离子浓度和诱导细胞凋亡来增强顺铂对食管癌的化疗疗效。
Int J Oncol. 2025 Apr;66(4). doi: 10.3892/ijo.2025.5738. Epub 2025 Mar 14.
8
Postoperative complications and health-related quality of life after oesophageal cancer surgery: a national, population-based cohort study.食管癌手术后的术后并发症及健康相关生活质量:一项基于全国人群的队列研究。
Acta Oncol. 2024 Dec 27;63:974-981. doi: 10.2340/1651-226X.2024.41290.
9
An Editorial on Salvage Esophagectomy for Esophageal Cancer.一篇关于食管癌挽救性食管切除术的社论。
Ann Surg Oncol. 2025 Apr;32(4):2260-2262. doi: 10.1245/s10434-024-16786-5. Epub 2025 Jan 4.
10
The Impact of Tumor Stage and Histopathology on Survival Outcomes in Esophageal Cancer Patients over the Past Decade.过去十年肿瘤分期和组织病理学对食管癌患者生存结局的影响。
Med Sci (Basel). 2024 Dec 9;12(4):70. doi: 10.3390/medsci12040070.